Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study.
Nicole BrighiFrancesco PanzutoRoberta ModicaFabio GelsominoManuela AlbertelliSara PuscedduSara MassironiGiuseppe LambertiMaria RinzivilloAntongiulio FaggianoAndrea SpallanzaniDiego FeroneNatalie PrinziRoberta Elisa RossiBruno AnnibaleAnna Maria ColaoDavide CampanaPublished in: The oncologist (2019)
The results of this study confirm an increased rate of gallstones development and related complications in patients with neuroendocrine tumors (NETs) treated with somatostatin analogs (SSAs). NETs of the gastrointestinal (GI) tract and related surgery are independent risk factors for biliary stone disease development. Therefore, all patients with primary GI-NET or undergoing abdominal surgery should be considered for prophylactic cholecystectomy. Data on other subgroups are not exhaustive, and management also evaluating additional clinical features (life expectancy, surgical and anesthesiological risks) should be considered. Prophylactic treatment with ursodeoxycholic acid does not seem to be a protective factor for SSA-related biliary stone disease.
Keyphrases
- neuroendocrine tumors
- minimally invasive
- molecular docking
- electronic health record
- risk assessment
- coronary artery disease
- newly diagnosed
- machine learning
- climate change
- deep learning
- editorial comment
- coronary artery bypass
- artificial intelligence
- combination therapy
- molecular dynamics simulations
- smoking cessation